Lodipressin

RSS

amlodipine

Refused
This medicine was refused authorisation for use in the European Union.

Overview

On 15 January 2015, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Lodipressin, intended for the treatment of systemic arterial hypertension in cats. The company that applied for authorisation is Le Vet Beheer B.V.

The applicant requested a re-examination of the opinion. After considering the grounds for this request, the CVMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 7 May 2015.

This EPAR was last updated on 29/04/2016

Application details

Product details
Name
Lodipressin
Active substance
Amlodipine besylate
International non-proprietary name (INN) or common name
amlodipine
Species
Cats
Application details
Marketing-authorisation applicant
Le Vet Beheer B.V.
Date of opinion
07/05/2015
Date of refusal of marketing authorisation
08/07/2015

Assessment history

How useful was this page?

Add your rating